rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

ADC Therapeutics SA Common Shares

ADCT · NYSE

Health CareBiotechnologyNot moving yet

ADCT stood above a rising 150-day average in 19 of the last 52 weekly readings, and has been out of that trend for the last 26 weeks. It is 34.4% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 26
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$39.3M
Officials’ trades on record
0
Institutions holding
111 (-2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 19 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$35.1M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months6
Buyers · sellers0 · 2
WhoDidSharesTraded
Redmile Group, Llc10% ownersold2,634,506at $3.282 Apr 2026filed 2 Apr 2026
Redmile Group, Llc10% ownersold2,529,491at $3.282 Apr 2026filed 2 Apr 2026
Redmile Group, Llc10% ownersold169,265at $3.801 Apr 2026filed 2 Apr 2026
Redmile Group, Llc10% ownersold162,517at $3.801 Apr 2026filed 2 Apr 2026
Redmile Group, Llc10% ownersold196,229at $3.7531 Mar 2026filed 2 Apr 2026
Redmile Group, Llc10% ownersold188,407at $3.7531 Mar 2026filed 2 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders111-2 on the quarter
New · exited28 · 30
Reported value$86.4M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Nantahala Capital Management, LLCadded · filed 14 Aug 202612,326,184$13.2M+6,728,751+120.2%
Redmile Group, LLCreduced · filed 14 Aug 202611,526,710$12.3M-3,943,792−25.5%
TCG Crossover Management, LLCunchanged · filed 14 Aug 202611,390,175$12.2M00.0%
Prosight Management, LPreduced · filed 14 Aug 20267,824,749$8.4M-475,251−5.7%
BlackRock, Inc.added · filed 7 Aug 20267,020,093$7.5M+769,346+12.3%
Point72 Asset Management, L.P.added · filed 14 Aug 20263,649,144$3.9M+267,015+7.9%
MORGAN STANLEYreduced · filed 13 Aug 20263,051,173$3.3M-761,409−20.0%
MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 20262,899,535$3.1M-219,619−7.0%
CITADEL ADVISORS LLCadded · filed 14 Aug 20262,053,316$2.2M+1,653,595+413.7%
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 20261,914,424$2.0M+261,398+15.8%
31 Mar 2023 – 30 Jun 2026
3774110Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Ameet Mallik Company insiderChief Executive Officer · last 30 Jun 20260 · 1
Jose Carmona Company insiderChief Financial Officer · last 30 Jun 20260 · 0
Mohamed Zaki Company insiderChief Medical Officer · last 30 Jun 20260 · 0
Peter J. Graham Company insiderChief Legal Officer · last 30 Jun 20260 · 0
Jean-Pierre Bizzari Company insiderDirector · last 3 Jun 20260 · 1
Peter Hug Company insiderDirector · last 3 Jun 20260 · 1
Robert Azelby Company insiderDirector · last 3 Jun 20260 · 1
Ron Squarer Company insiderDirector · last 3 Jun 20260 · 1
Timothy Coughlin Company insiderDirector · last 3 Jun 20260 · 0
Victor Sandor Company insiderDirector · last 3 Jun 20260 · 1
Viviane Monges Company insiderDirector · last 3 Jun 20260 · 1
Redco Ii Master Fund, L.p. Company insider10% owner · last 2 Apr 20261 · 4

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202592.9%
Operating profit marginFY 2025 · to 31 Dec 2025-149%
Free cash flow marginFY 2025 · to 31 Dec 2025-174%
Return on capital employedFY 2025 · to 31 Dec 2025-48.0%
Interest coverFY 2025 · to 31 Dec 2025-7.47×
Research spendFY 2025 · to 31 Dec 2025128%
Share count trendFY 2025 · to 2 Mar 20261.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$261.3M
Free cash flowFY 2025 · to 31 Dec 2025−$141.4M

Analyst forecasts

No analyst forecasts yet.